Related Experiment Video
Updated: May 12, 2026
08:05
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Profound sedation with propofol modifies atrial fibrillation dynamics
Raquel Cervigón1, Javier Moreno, Julián Pérez-Villacastín
1Universidad de Castilla7#x02010;La Mancha, DIEEAC, UCLM, Bioengineering Innovation Research Group (GIBI), Cuenca, Spain.
Pacing and Clinical Electrophysiology : PACE
|April 27, 2013
Summary
This review explores how propofol, a common anesthetic, may affect atrial fibrillation (AF) by altering atrial cell electrical activity and atrioventricular conduction, effects potentially overlooked in standard clinical studies.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation (AF) involves complex electrical wave propagation in the atria.
- Antiarrhythmic drugs target cardiac ionic currents to manage AF.
- Subtle drug effects on ionic currents may be unmasked at high atrial rates seen in AF.
Purpose of the Study:
- To review the impact of propofol sedation on atrial electrophysiology and atrioventricular (AV) conduction during AF.
- To assess whether propofol's effects on AF dynamics have been systematically overlooked in clinical research.
Main Methods:
- Analysis of AF propagation patterns before and after propofol infusion in patients undergoing pulmonary vein ablation.
- Review of existing studies on propofol's effects on atrial cells and AV conduction.
Main Results:
- Propofol's influence on AF propagation dynamics requires further investigation.
- Potential subtle effects of propofol on cardiac ionic currents at high activation rates are discussed.
- Impact on atrioventricular conduction is also considered.
Conclusions:
- Propofol's potential to influence atrial fibrillation dynamics warrants consideration.
- Further research is needed to elucidate propofol's precise electrophysiological effects in the context of AF.
- The study highlights a potential gap in understanding anesthetic agents' impact on cardiac arrhythmias.
Related Concept Videos
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...